Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HIV-1 infection
|
94 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2005 | 2005 | |||||
Neoplasm Metastasis
|
327 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.050 | 1.000 | 5 | 2007 | 2013 | |||||
Colorectal Carcinoma
|
1962 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.020 | 1.000 | 2 | 2007 | 2018 | |||||
Malignant neoplasm of colon and/or rectum
|
502 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.020 | 1.000 | 2 | 2007 | 2018 | |||||
Colon Carcinoma
|
275 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2007 | 2007 | |||||
Malignant tumor of colon
|
688 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2007 | 2007 | |||||
Breast Carcinoma
|
2793 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.060 | 1.000 | 6 | 2009 | 2017 | |||||
Malignant neoplasm of breast
|
3417 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.060 | 1.000 | 6 | 2009 | 2017 | |||||
Liver carcinoma
|
942 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.020 | 1.000 | 2 | 2009 | 2018 | |||||
Lymphoma, Non-Hodgkin
|
197 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.020 | 1.000 | 2 | 2009 | 2018 | |||||
Neoplasms
|
1644 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.020 | 1.000 | 2 | 2009 | 2011 | |||||
Adult Hodgkin Lymphoma
|
27 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2009 | 2009 | |||||
Adult Non-Hodgkin Lymphoma
|
39 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2009 | 2009 | |||||
Childhood Hodgkin Lymphoma
|
29 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2009 | 2009 | |||||
Childhood Non-Hodgkin Lymphoma
|
39 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2009 | 2009 | |||||
Hodgkin Disease
|
148 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2009 | 2009 | |||||
Lymphoma, Non-Hodgkin, Familial
|
79 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2009 | 2009 | |||||
Myocardial Infarction
|
680 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.030 | 0.667 | 3 | 2010 | 2017 | |||||
Malignant Neoplasms
|
1641 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.040 | 1.000 | 4 | 2011 | 2018 | |||||
Primary malignant neoplasm
|
1374 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.030 | 1.000 | 3 | 2011 | 2018 | |||||
Ovarian Failure, Premature
|
115 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||
Premature Menopause
|
90 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||
SVEINSSON CHORIORETINAL ATROPHY
|
30 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||
Infections specific to perinatal period
|
1 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||
Acute lymphocytic leukemia
|
222 | 0.611 | 0.600 | 10 | 44372809 | 3 prime UTR variant | C/T | snv | 0.16 | 0.010 | 1.000 | 1 | 2013 | 2013 |